Component,Publication Grant Number,Publication Doi,Publication Journal,Pubmed Id,Pubmed Url,Publication Title,Publication Year,Publication Keywords,Publication Authors,Publication Abstract,Publication Assay,Publication Tumor Type,Publication Tissue,Publication Dataset Alias,Publication Accessibility,PublicationView_id,Id,entityId
PublicationView,CA253547,10.1126/scitranslmed.adi0069,Sci Transl Med,37672566,https://pubmed.ncbi.nlm.nih.gov/37672566,Intratumoral drug-releasing microdevices allow in situ high-throughput pharmaco phenotyping in patients with gliomas,2023,,"Pierpaolo Peruzzi, Christine Dominas, Geoffrey Fell, Joshua D Bernstock, Sarah Blitz, Debora Mazzetti, Mykola Zdioruk, Hassan Y Dawood, Daniel V Triggs, Sebastian W Ahn, Sharath K Bhagavatula, Shawn M Davidson, Zuzana Tatarova, Michael Pannell, Kyla Truman, Anna Ball, Maxwell P Gold, Veronika Pister, Ernest Fraenkel, E Antonio Chiocca, Keith L Ligon, Patrick Y Wen, Oliver Jonas","The lack of reliable predictive biomarkers to guide effective therapy is a major obstacle to the advancement of therapy for high-grade gliomas, particularly glioblastoma (GBM), one of the few cancers whose prognosis has not improved over the past several decades. With this pilot clinical trial (number NCT04135807), we provide first-in-human evidence that drug-releasing intratumoral microdevices (I(Read more on Pubmed)",Pending Annotation,Pending Annotation,Pending Annotation,,Restricted Access,37672566,2a29bdab-facc-4c6b-b568-8551ce7e5ead,syn52566231
